Does Cosentyx Reduce Vaccine Effectiveness?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, can lower immune responses to certain vaccines. Clinical data show it impairs protection against non-live vaccines like tetanus toxoid and pneumococcal vaccines. In trials, antibody responses dropped by 40-50% compared to placebo, particularly for pneumococcal serotypes.[1][2]
Live vaccines are contraindicated due to infection risk from immunosuppression.[3]
Which Vaccines Are Most Affected?
- Pneumococcal and tetanus: Reduced seroprotection in 20-50% of patients on Cosentyx, based on phase 3 studies.[1]
- Influenza: Limited data; one study found no major drop in response, but experts recommend caution.[4]
- COVID-19 mRNA vaccines: Real-world evidence suggests modestly lower antibody levels post-vaccination, though cellular immunity holds up better. Protection against severe disease remains strong.[5]
- Shingles (herpes zoster): Live vaccine avoided; recombinant version (Shingrix) preferred, with good but potentially blunted response.[2]
Guidelines advise vaccinating before starting Cosentyx or using boosters.[3]
How Does This Compare to Other Biologics?
| Drug | Vaccine Impact | Key Difference |
|------|----------------|---------------|
| Cosentyx (IL-17) | Moderate on non-live; live contraindicated | Less broad suppression than TNF inhibitors |
| Humira (adalimumab, TNF) | Stronger reduction in pneumococcal/influenza response | Higher infection risk overall [6] |
| Stelara (ustekinumab, IL-12/23) | Minimal impact on most vaccines | Better preserved responses [4] |
| Skyrizi (risankizumab, IL-23) | Similar to Cosentyx; data emerging | Fewer head-to-head trials [2] |
TNF blockers like Humira pose higher risks for live vaccines and overall immunogenicity.[6]
What Do Guidelines Say for Patients?
ACR and EULAR recommend:
- Complete vaccinations pre-treatment.
- Avoid live vaccines during therapy.
- Prioritize high-risk vaccines (e.g., pneumococcal, influenza) with monitoring.[3][7]
No increased breakthrough infections reported in Cosentyx trials, but real-world vigilance advised for immunocompromised patients.[1]
When to Get Vaccinated on Cosentyx?
Best before starting (up to 4 weeks prior). If already on it:
- Use inactivated vaccines.
- Check titers for tetanus/pneumococcal if high-risk.
- Annual flu shots still beneficial despite partial response.[4]
Consult rheumatologist; no patent issues affect this (Cosentyx patents expire 2027-2031 in major markets).8
[1]: Cosentyx prescribing information, Novartis, 2023. Link
[2]: Bagel et al., J Am Acad Dermatol, 2020. PubMed
[3]: CDC/ACIP guidelines on immunomodulators, 2022. Link
[4]: Furer et al., Rheumatology, 2021. PubMed
[5]: Winthrop et al., Lancet Rheumatol, 2022 (COVID data). PubMed
[6]: Keystone et al., Ann Rheum Dis, 2019 (TNF comparison). PubMed
[7]: EULAR recommendations, 2023. Link